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The Drosophila drosulfakinin (dsk) gene encodes the 
cholecystokinin homologues drosulfakinin-I (DSK-I) and 
drosulfakinin-II (DSK-II). The naturally occurring DSK- 
I peptide was isolated from an extract of adult flies and 
its sequence determined by automated Edman degrada- 
tion and sequence-specific radioimmunoassay. The dsk 
cDNA is expressed during the larval, pupal, and adult 
stages of development and is an abundant adult head 
transcript. Sequence-specific DSK antibodies localized 
DSK expression in the Drosophila larval central nervous 
system to medial neurosecretory cells and projections that 
extend from the neurons anteriorly into the brain and 
posteriorly down the ventral ganglion. The availability 
of the dsk transcript, sequence-specific DSK antibodies 
and the application of molecular genetics provide the op- 
portunity to elucidate the role(s) of Drosophila CCK ho- 
UIOlOgUeS in brain StrUCtUrt? and fUUCtiOU. 0 iv92 Academic 
Press, Inc. 
INTRODUCTION 
Neural peptides constitute an important class of mes- 
sengers acting as transmitters, regulators, and/or hor- 
mones (1). During the past decade, an increasing number 
of peptides have been isolated and characterized from 
vertebrate neural tissue. Some of these peptides were 
known to be present in nonneural vertebrate tissues, as 
well as in lower species. The conservation of sequence, 
widespread distribution, and abundance of these peptides 
suggests that they may play important roles in neural 
function. 
Cholecystokinin (CCK) and gastrin are members of a 
family of peptides that have long been recognized as gas- 
trointestinal peptide hormones. Gut CCK and gastrin 
function as hormonal regulators of various digestive pro- 
cesses and feeding behaviors. Although originally isolated 
1 The drosulfakinin gene is referred to as dsk using lowercase letters 
since it has not been established whether the gene is dominant or re- 
cessive. The drosulfakinin peptides are designated DSK analogous to 
CCK and LSK peptides. 
from the gut, CCK is now known to be one of the most 
abundant vertebrate brain peptides (2). Extensive studies 
on the possible neural function of CCK have led to nu- 
merous suggestions as to its physiological role(s). For in- 
stance, it is thought that neural CCK may be involved in 
feeding behavior, in mediation of painful stimuli, in mod- 
ulation of dopaminergic function, and in induction of 
panic-like attacks (3, 4). 
CCK-like immunoreactive materials have been iden- 
tified in numerous invertebrates. Leucosulfakinin (LSK) 
and leucosulfakinin-II (LSK-II) peptides isolated from 
cockroach head share C-terminal sequence homology with 
CCK peptides (5, 6). Contraction of visceral muscle pro- 
moted by LSK peptides in cockroach hindgut and its at- 
tendant stimulation of hemolymph circulation are anal- 
ogous to CCK-induced motility and increased circulation 
in mammalian intestine. 
Analysis of the Drosophila drosulfakinin (dsk) DNA 
sequence suggests that two CCK-like peptides (DSK-I 
and DSK-II) are processed from the precursor by post- 
translational processing at basic amino acid residues (7, 
8). Although conversion of a precursor to final products 
most commonly occurs at adjacent basic amino acid res- 
idues or at single arginyi residues (9, lo), not all of these 
possible cleavage sites are utilized. It appears that both 
primary and secondary structural features are important 
for determining processing sites. As a result, it is not pos- 
sible to predict with certainty what the final products of 
processing will be solely on the basis of the deduced se- 
quence of the precursor. Although deduction of amino 
acid sequence from DNA has become a common first step 
in predicting bioactive peptides, it is important to isolate 
and structurally characterize naturally occurring peptides. 
FMRFamide (PheMetArgPheNH,) and FMRFamide- 
containing peptides are widely distributed among inver- 
tebrates and share an identical -MetArgPheNH2 C-ter- 
minal sequence with DSK peptides. Antiserum to 
FMRFamide stains a certain subset of neurons in Dro- 
sophila (11). However, since the specificity of the anti- 
serum was to the C-terminal amino acids -ArgPheNHz, 
the immunohistochemical data cannot be interpreted un- 
ambiguously. A recent study to map the sites of 
1044.7431/92 $5.00 
Copyright 0 1992 by Academic Press, Inc. 
All rights of reproduction in any form reserved. 
342 
Drosophila DSK-I EXPRESSION 343 
FMRFamide expression in the Drosophila nervous system 
using peptide antibodies that recognize proFMRFamide 
and the N-terminus of DPKQDFMRFamide, a peptide 
encoded in proFMRFamide, localized FMRFamide-spe- 
cific expression to cells in the Drosophila ventral ganglion 
(12, 13). 
To begin the study of the role of Drosophila CCK ho- 
mologues in brain structure and function, experiments 
were undertaken to isolate DSK-I and confirm its expres- 
sion in neural tissue. This paper reports the structural 
characterization of the naturally occurring Drosophila 
cholecystokinin homologue, DSK-I, and its expression in 
neural tissue. The naturally occurring DSK-I peptide was 
isolated and a sequence-specific antisera was used to lo- 
calize DSK-specific expression to the medial neurosecre- 
tory cells in the larval central nervous system. 
METHODS 
Production of antibody. The peptide PheAspAsp- 
TyrGlyHisMetArgPheNHz corresponding to DSK-I was 
synthesized using an Applied Biosystems model 430A 
solid phase peptide synthesizer. The peptide was purified 
by preparative reversed-phase and ion exchange HPLC. 
The structure of the synthetic DSK-I peptide was con- 
firmed by mass spectrometry, amino acid analysis, and 
automated Edman degradation. Mass was determined by 
fast atom bombardment mass spectrometry (FAB MS) 
using a Kratos MS-50 mass spectrometer. The matrix 
was thioglycerol and ions were detected in the positive 
mode and peak matching was against cesium iodide ion 
clusters. Amino acid analysis was done after acid hydro- 
lysis in 6 N HCl for 24 h at 110°C in uacuo. The hydro- 
lysate was dried under a nitrogen stream and the analysis 
done on a Beckman 6300 amino acid analyzer using stan- 
dard operating conditions. The synthetic peptide was se- 
quenced on an Applied Biosystems Model 470 automated 
protein sequencer with on-line detection of PTH-amino 
acids using standard operating conditions. 
Antibody was raised in two New Zealand white rabbits 
to DSK-I conjugated to succinylated thyroglobulin via 
carbodiimide coupling (14). The initial immunization was 
by intradermal injections at multiple sites using a total 
of 1 mg antigen emulsified in Freund’s complete adjuvant. 
Subsequent boosts were given every 2 weeks by subcu- 
taneous injections of 0.5 mg antigen in Ribi adjuvant 
system (Ribi Immunochem Research). The titer was 
monitored by a solid phase dot blot assay for small 
peptides (15). 
Because DSK and FMRFamide peptides have an iden- 
tical C-terminal sequence, polyclonal antibody to DSK-I 
would yield ambiguous localization data. Analysis of the 
antisera by solid phase dot blot assay indicated that the 
unpurified antisera recognized both DSK-I and 
FMRFamide peptides. Antibody used for DSK localiza- 
tion studies was selected for by binding the antibodies 
that recognized the common C-terminus to a FMRFamide 
peptide affinity column. The FMRFamide peptide affinity 
column capacity was three times greater than the amount 
of antisera applied. Antibody was passed over the column 
two times and antibody not bound to the column was 
assayed by dot blot. The unbound antibody recognized 
synthetic DSK-I but did not recognize FMRFamide, CCK, 
or neuropeptide Y, a peptide without sequence homology; 
this antibody is referred to as sequence-specific DSK an- 
tibody. The antibody bound to the column was released 
using 0.1 M citrate, pH 2.5, and recognized both DSK 
and FMRFamide peptides. 
Isolation of the naturally occurring DSK-Ipeptide. The 
unpurified antibody was found suitable for a general ra- 
dioimmunoassay to detect peptides containing a C-ter- 
minal -ArgPheNHz. Synthetic DSK-I was iodinated using 
Iodogen (Pierce) (16). Antigens were detected using a 
competition radioimmunoassay (17). The solid phase 
matrix was provided by adding Staphylococcus aureus 
membranes (Calbiochem). The amount of antiserum used 
was determined by titrating the antibody with labeled 
antigen to yield a strong signal. To quantitate the level 
of antigen in the column fractions, serial dilutions of the 
antigen test solution were made and a standard curve was 
generated for each radioimmunoassay. Each experimental 
and standard curve sample was done in triplicate. A typ- 
ical assay included: 5-~1 column fraction, 20 ~1 washed S. 
aureus membranes, 10 ~1 antiserum diluted l:lOOO, 2 ~1 
lz51-labeled DSK-I, and 185 ~1 buffer (3% BSA/PBS with 
0.02% sodium azide). Background was determined by in- 
cluding a sample without labeled antigen and one without 
antibody. 
Six hundred grams of adult D. melanogaster raised on 
standard corn meal agar media at room temperature was 
homogenized in methanol/water/acetic acid, 900:90:10, 
containing 25 pg/ml Pepstatin A (Bachem). The extract 
was centrifuged, the pellet was reextracted with acidic 
methanol, and the second extract was centrifuged. The 
supernatants were combined, freeze-dried, and washed 
with diethyl ether. The freeze-dried extract was suspended 
in 1 N formic acid and then applied to a Sephadex G-25 
(Pharmacia) 4.5 X loo-cm column that had been equili- 
brated with 1 N formic acid. Two-milliliter fractions were 
collected and assayed for immunoreactivity as described 
above. Fractions from each of the two major immuno- 
reactive peaks were combined separately, diluted and then 
subjected to a desalting, concentrating step using SepPak 
(Waters) cartridges. Peptides were eluted from the 
SepPak using 50% acetonitrile, 0.1% TFA with no loss 
of immunoreactivity observed after this desalting proce- 
dure. 
The desalted fractions from the Sephadex G-25 column 
were diluted 3 to 1 with 5 mM sodium phosphate, pH 3.0, 
25% acetonitrile and applied to a Polysulfoethyl aspar- 
tamide ion exchange column, 9.3 mm X 20 cm (PolyLC) 
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(18), equilibrated with Buffer A (5 n-&f sodium phosphate, 
pH 3.0,25% acetonitrile). The operating conditions were: 
Buffer A for 10 min after injection, to 20% Buffer B (200 
mM sodium phosphate, pH 3.0, 25% acetonitrile) at 80 
min, to 40% Buffer B at 90 min, and held at 40% Buffer 
B for 5 min with a flow rate of 1.2 ml/min. Fractions were 
collected on the basis of absorbance measured at Azz5. 
Five-microliter aliquots of each fraction were analyzed by 
radioimmunoassay. 
Immunoreactive material was further purified on a 
PLRPS reversed-phase column (100 A), 4.6 mm X 25 cm 
(Polymer Labs), and peptides were eluted with a linear 
gradient of 0 to 40% acetonitrile plus 0.1% TFA in 60 
min. The flow rate was 0.7 ml/min and fractions were 
collected based on absorbance measured at Azz5. Five- 
microliter aliquots of each fraction collected were analyzed 
by radioimmunoassay. The immunoreactive material 
identified was frequently subjected to further purification 
by microbore reversed-phase HPLC and the purified ma- 
terial sequenced on an Applied Biosystems Model 470 
automated protein sequencer with on-line detection of 
PTH-amino acids using standard operating conditions. 
Northern blot analysis. Total RNA from various de- 
velopmental stages was isolated (19), poly(A)+ RNA en- 
riched (20), and 10 pg poly(A)+ RNA fractionated by size 
on a formaldehyde gel. The hybridization probe, a 780- 
bp EcoRI-EcoRI dsk fragment containing both DSK-I 
and DSK-II (8), was 32P-labeled by nick-translation to 
approximately lo8 cpm/pg. The gel was blotted to Nytran 
membrane; hybridized at 65”C, 6X SSC, 2X Denhardt’s 
solution, 0.5% SDS; washed at 65°C 6X SSC, 0.1% SDS; 
and exposed to Kodak XAR 5 film with one intensifying 
screen at -80°C for 4 days. 
Immunohistochemical localization of DSK pep- 
tides. Third instar larval neural tissue was dissected in 
cold Ringer’s solution and prepared for immunohisto- 
chemistry according to White et al. (11). Whole mount 
preparations fixed in paraformaldehyde and washed in 
PBS were incubated for 2 h at 4°C with sequence-specific 
DSK antibody, washed extensively, and then incubated 
for 2 h at 4°C with FITC-labeled anti-rabbit antibody 
(Sigma). Controls included no antibody, no second anti- 
body, and antibody preabsorbed for 2 h at 4°C with DSK- 
I, FMRFamide, or CCK at concentrations of 0.1 and 
0.0001 M. 
RESULTS AND DISCUSSION 
Isolation of the naturally occurring Drosophila DSK-I 
peptide. The first step in the purification of peptides 
from the Drosophila homogenate was to separate an acidic 
methanol extract of adult flies based on size using a Seph- 
adex G-25 column. Two major peaks of -ArgPheNHz-like 
immunoreactivity were observed after gel exclusion frac- 
tionation of the Drosophila extract (Fig. 1). Since - 
ArgPheNHz-containing peptides isolated to date and 
Fraction number 
FIG. 1. Sephadex G-25 profile of Drosophila homogenate. Elution 
profile of acidic methanol extract of 600 g of adult D. melanogaster on 
Sephadex G-25 (4.5 X 100 cm). Peptides were eluted from the column 
using 1 N formic acid. Two-milliliter fractions were collected at a flow 
rate of 35 ml/h. Five-microliter aliquots of fractions 161-531 were an- 
alyzed by radioimmunoassay. No immunoreactive material was present 
in fractions 161-410. Void volume and salt volume correspond to frac- 
tions 161 and 531, respectively. Molecular weight standards (Sigma) 
are indicated by arrows: bovine serum albumin, 66,000 Da; ovalbumin, 
43,000 Da; carbonic anhydrase, 29,000 Da; lysozyme, 14,300 Da; and p- 
chain insulin, 3200 Da. 
those that can be predicted from DNA precursors are 
fairly similar in size, it was then necessary to take ad- 
vantage of the independent physical parameters of charge 
and hydrophobicity to separate the structurally related 
peptides. Ion exchange and reversed-phase (Fig. 2) HPLC 
were used to further purify the immunoreactive species. 
The purified immunoreactive material present as a single 
peak in fraction 56 from the PLRPS column was further 
purified by microbore reversed-phase HPLC (data not 
shown) and subjected to automated Edman degradation 
which identified nine amino acid residues (Table 1). Ed- 
man sequencing does not provide information regarding 
the presence of a C-terminal amide. However, the ra- 
dioimmunoassay used requires a C-terminal amide as part 
of the recognition site. Taken together these data identify 
the sequence of the peptide as PheAspAspTyrGly- 
HisMetArgPheNH,. The sequence determined for the 
naturally occurring peptide is the same as the sequence 
of the DSK-I peptide predicted from the drosulfakinin 
precursor. The recovery of DSK-I from the acidic meth- 
anol extraction of 600 g of flies was approximately 0.18 
nmol based on radioimmunoassay data. 
Expression of Drosophila dsk RNA. To study dsk de- 
velopmental expression, poly(A)+ RNA was isolated from 
larvae, pupae, and adult whole bodies. Northern blot 
analysis indicates that the dsk transcript is expressed in 
all three developmental stages in approximately equal 
amounts. In addition to isolating RNA from adult whole 
body, RNA was also isolated from adult head. The North- 
ern blot data from adult head poly(A)+ RNA (Fig. 3) and 
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FIG. 2. PLRPS column profile. Separation of Polysulfoethyl as- 
partamide column fractions 60-64 on PLRPS (100 A) column. Buffer 
A was 0.1% TFA in water. Buffer B was 0.1% TFA in acetonitrile. The 
gradient was 0 to 40% in 60 min. The flow rate was 0.7 ml/min. Five- 
microliter aliquots were analyzed. An arrow indicates the PLRPS fraction 
(No. 56) containing immunoreactive material identified as PheAsp- 
AspTyrGlyHisMetArgPheNH,. 
the in situ hybridization of adult head tissue (8) indicate 
that dsk RNA is an abundant head transcript. The ob- 
servation that both drosulfakinin and cholecystokinin are 
abundant brain transcripts provides further evidence 
suggesting that drosulfakinin is a Drosophila CCK ho- 
mologue. 
Immunohistochemical localization of Drosophila DSK 
peptides. Sequence-specific DSK-specific antibody was 
used to localize DSK-immunoreactive material present 
in the Drosophila larval central nervous system. The larval 
nervous system consists of two paired brain lobes and the 
ventral ganglion. The ventral ganglion is composed of the 
subesophageal ganglion which is most anterior, followed 
by the three thoracic ganglia, and then by the seven ab- 
dominal ganglia. The description of the cell identity and 
number is based on whole mounts processed according to 
the immunofluorescence technique of White et al. (11). 
Immunofluorescence representing DSK-specific expres- 
sion was observed in the larval brain lobes in bilaterally 
symmetric cells identified as the MPl medial neurose- 
cretory cells (Fig. 4A) and projections that extend from 
the cell bodies down the ventral ganglion and anterior 
into the brain lobes (Fig. 4B). The projections from the 
medial neurosecretory cell extending down the length of 
TABLE 1 
Automated Edman Sequencing Amino Acid Yields of 
Drosophila DSK-I Peptide at Each Step 
PheAspAspTyrGlyHisMetArgPheNH, 






























the ventral ganglion indicate that the DSK peptides may 
function at positions some distance from the site of pro- 
duction. Projections to the abdominal ganglia are consis- 
tent with drosulfakinin peptides being cholecystokinin 
homologues due to the presence of CCK-immunoreactive 
neurons in the vertebrate gut. 
Control studies indicate that the immunofluorescence 
is DSK-specific expression since preabsorption of the se- 
quence-specific antibody with DSK-I completely abol- 
ished all signal (data not shown), while after preabsorp- 






FIG. 3. Northern blot analysis of Drosophila dsk transcript. 
Poly(A)+ RNA (10 pg) from third instar larvae, pupae, adult whole body, 
and adult head were hybridized to “P-labeled nick-translated dsk DNA 
fragment containing DSK peptides. Molecular size standards are indi- 
cated in base pairs. The blot was probed with a ribosomal protein DNA 
clone (rp49) from M. Rosbash (Brandeis) as a control for equal amounts 
of RNA present in each lane (data not shown). 
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FIG. 4. Expression of DSK peptides in a whole mount larval brain preparation. Third instar brains were dissected and incubated with 
sequence-specific antisera against DSK-I and then incubated with FITC-labeled anti-rabbit antibody. (A) A whole mount preparation of a third 
instar larval central nervous system. Fluorescence is observed from the MPl medial neurosecretory cells and projections extending down the 
ventral ganglion, Bar represents 50 pm. (B) A more dorsal plane of focus of the same preparation at a higher magnification illustrates that 
projections extend anteriorly from the MPl cells. The MPI cells are out of focus and appear as blurred images posterior to the projections. In 
addition, less intense signal is observed from anterior neurosecretory cells. Bar represents 10 pm. 
pattern and intensity of fluorescence were observed. Lar- 
val preparations incubated with either first or second an- 
tibody alone resulted in no observable fluorescence. 
Since DSK-II is a five-amino acid N-terminal extension 
of the DSK-I amino acid sequence, it is important to con- 
sider the sequence relatedness of DSK peptides when in- 
terpreting the immunolocalization data. The sequence- 
specific DSK antibody recognizes both DSK-I and DSK- 
II and the fluorescent signals observed in these studies 
could be due to either one or both of the DSK peptides. 
An antibody directed toward the five-amino acid N-ter- 
minal sequence of DSK-II would help to distinguish be- 
tween DSK-I and DSK-II. Antiserum that distinguishes 
between DSK-I and DSK-II should provide the oppor- 
tunity to determine whether both DSK-I and DSK-II are 
processed in the same cells and at the same developmental 
stages. 
Chin et al. (12) and Schneider et al. (13) have used 
antibodies specific to Drosophila proFMRFamide and 
DPKQDFMRFamide to study FMRFamide expression. 
Since the FMRFamide-specific antibodies recognize neu- 
rons present in the thoracic ganglia and not in the brain, 
the cells that produce FMRFamide peptides are different 
from those expressing DSK peptides. The unique distri- 
bution of the cells containing abundant DSK-immuno- 
reactive material and the high level of expression of the 
dsk transcript throughout the various developmental 
stages support the hypothesis that DSK peptides are im- 
portant to neural function. The well-defined and specific 
nature of the expression of these two structurally related 
neural peptide families provides a unique opportunity for 
studying neural peptide expression and function utilizing 
molecular genetic techniques in Drosophila. 
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